<DOC>
	<DOCNO>NCT02866136</DOCNO>
	<brief_summary>Conservative treatment retinoblastoma ( RETINO 2011 ) 1 . -Multicentric non randomise , phase II study patient treat chemoreduction ( VP16 , carboplatin ) follow chemothermotherapy without laser treatment day 8 2 . -Multicentric non randomise , phase II study patient bilateral asymmetric dis-ease ( Group D eye one eye ) unilateral presentation group B/C/D accord age vitreous seed 3 . - Multicentric non randomise , phase II study patient treat 6 cycle three drug regimen local treatment bilateral group D eye eye .</brief_summary>
	<brief_title>Conservative Treatments Retinoblastoma</brief_title>
	<detailed_description />
	<mesh_term>Retinoblastoma</mesh_term>
	<mesh_term>Retinal Neoplasms</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Study 1 inclusion criterion : Patients affect unilateral retinoblastoma group A , B ( accord age ) , group C ( accord age vitreous seed ) , bilateral retinoblastoma group A , B , C ( exclude eye macular threat bilateral group D eye remain eye ) amenable conservative treatment ( least one eye bilateral disease ) need initial chemotherapy location , size lesion ( 4 mm diameter ) , vision threat risk intravitreal relapse make patient amenable chemothermotherapy first line . Patients less six month age unilateral retinoblastoma group B , C , D , bilateral asymmetric one eye group D amenable local treatment without chemotherapy . Children 0 6 year old . Study 2 inclusion criterion : Patients affect unilateral bilateral retinoblastoma group B ( accord age ) , group C ( accord age vitreous seed ) , group D. Patients affect bilateral retinoblastoma asymmetric group D eye treat intraarterial chemotherapy Melphalan amenable local treatment without chemotherapy . Children 6 month 6 year old . Study 3 inclusion criterion : Children affect bilateral group D retinoblastoma eye amenable conservative treatment . Children 0 6 year old . Common inclusion criterion : Patients previously treat chemotherapy radiotherapy tumour another cancer . No contraindication study treatment Possible long term followup . Written inform consent parent legal representative . Patients social security cover . Study 1 exclusion criterion : Patients local treatment possible without initial chemotherapy ( tumour small 4 mm locate far optic nerve head macula ) . Patients unilateral group D massive tumour group E eye need enucleation first line initial chemotherapy ( case buphthalmia suspect optic nerve invasion extrascleral extension ) . Patients affect bilateral retinoblastoma asymmetric group D eye treat intraarterial chemotherapy Melphalan amenable local treatment without chemotherapy . Patients bilateral retinoblastoma bilateral group D eye remain eye present bilateral macular threat require conservative treatment 6 cycle , three drug regimen . Study 2 exclusion criterion : Patients unilateral group D ( extensive ) B C cover optic nerve head group E eye enucleation warrant first line chemotherapy ( case buphthalmia suspect optic nerve invasion extrascleral extension ) . Patients unilateral group D eye tumour volume 50 % eye volume , massive choroidal invasion could associate ( clinical imaging criterion ) enucleation warrant . Study 3 exclusion criterion : Patients local treatment possible without chemoreduction ( tumour small 4 mm , distant macula optic nerve head ) . Patients affect bilateral retinoblastoma asymmetric group D eye treat intraarterial chemotherapy Melphalan amenable local treatment without chemotherapy . Patients bilateral retinoblastoma without macular threat group A , B , C treat chemoreduction VP16 Carboplatin chemothermotherapy without laser day 8 . Common exclusion criterion : Patients older 6 year old . Patients extraocular retinoblastoma . Patients disease contraindication chemotherapy . Patients anteriorly treat chemotherapy . Patients anteriorly treat external beam irradiation . Patients anteriorly treat another cancer . Followup possible due geographic distance center social psychological reason . Parents accept therapeutic strategy explanation investigator . Contraindication use one drug use study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>